SCHEMBL1420183

SCHEMBL1420183

COc1ccc(C(C=O)c2ccc(O)cc2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 1/20 0.53
ESR2 Q92731 1/20 0.53
GAA P10253 1/20 0.50
PKM P14618 1/20 0.50
APP P05067 2/20 0.48
MAPT P10636 5/20 0.47
KMT2A Q03164 3/20 0.47
CALM1 P0DP23 2/20 0.46
MEN1 O00255 2/20 0.45
CYP3A4 P08684 2/20 0.45
PPARG P37231 1/20 0.45
ALDH1A1 P00352 2/20 0.45
P4HB P07237 1/20 0.45
RAB9A P51151 1/20 0.45
F3 P13726 1/20 0.45
XDH P47989 1/20 0.45
S100B P04271 1/20 0.45
TRIM24 O15164 1/20 0.44
TYR P14679 1/20 0.44
TRIM33 Q9UPN9 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4775938 0.90 ALDH1A1 (0.52) PKMMAPTKMT2AMEN1CYP3A4
SCHEMBL17083602 0.84 ESR1 (0.46) ESR2MAPTKMT2AMEN1CYP3A4
SCHEMBL4731187 0.84 TYR (0.49) LTA4HESR2GAAPKMMAPT
SCHEMBL7450991 0.84 CHRM2 (0.47) MAPTKMT2AMEN1TRIM24TYR
SCHEMBL1515694 0.83 ACP3 (0.56) LTA4HGAAMAPTKMT2ACYP3A4
SCHEMBL26999431 0.83 ACHE (0.58) GAAMAPTKMT2ACYP3A4ALDH1A1
SCHEMBL3955351 0.82 MEN1 (0.51) MAPTKMT2AMEN1CYP3A4PPARG
SCHEMBL8057378 0.81 MAPT (0.50) GAAMAPTKMT2AMEN1CYP3A4
SCHEMBL1694896 0.81 TDP1 (0.59) APPMAPTKMT2AMEN1CYP3A4
SCHEMBL9992962 0.81 APP (0.44) APPMAPTKMT2AMEN1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11873315-B2 Chiral n-heterocyclic phosphorodiamidic acids (NHPAS) and derivatives as novel Brønsted acid catalysts THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS (US) 2024-01-16 US disclosed
EP-2297133-A1 1, 2 DISUBSTITUTED HETEROCYCLIC COMPOUNDS Envivo Pharmaceuticals, Inc. (US) 2011-03-23 EP disclosed
WO-2009158393-A1 1, 2 DISUBSTITUTED HETEROCYCLIC COMPOUNDS ENVIVO PHARMACEUTICALS, INC. (US) 2009-12-30 WO disclosed
EP-1539757-A1 SUBSTITUTED PYRROLOPYRIDINES AstraZeneca AB (SE) 2005-06-15 EP disclosed
WO-2004016609-A1 SUBSTITUTED PYRROLOPYRIDINES ASTRAZENECA AB (SE) 2004-02-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11873315-B2 Chiral n-heterocyclic phosphorodiamidic acids (NHPAS) and derivatives as novel Brønsted acid catalysts ELANE, PNKP, SERPINB1 LTA4H 21/4885ESR2 2602/4885GAA 553/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.